Go Pro
→ The $15 Gold Fund That Pays Up to $1,152/Month (From Investors Alley) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Galmed Pharmaceuticals Ltd. stock logo
GLMD
Galmed Pharmaceuticals
$0.60
+3.3%		$0.58
$0.41
▼
$1.65
$3.83M0.74960,980 shs13,217 shs
(Almost) Everything You Need To Know About The EV Market Cover
(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Galmed Pharmaceuticals Ltd. stock logo
GLMD
Galmed Pharmaceuticals
+3.28%0.00%+5.27%-1.96%-58.69%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Galmed Pharmaceuticals Ltd. stock logo
GLMD
Galmed Pharmaceuticals
$0.60
+3.3%		$0.58
$0.41
▼
$1.65
$3.83M0.74960,980 shs13,217 shs
(Almost) Everything You Need To Know About The EV Market Cover
(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Galmed Pharmaceuticals Ltd. stock logo
GLMD
Galmed Pharmaceuticals
+3.28%0.00%+5.27%-1.96%-58.69%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Galmed Pharmaceuticals Ltd. stock logo
GLMD
Galmed Pharmaceuticals
1.00
SellN/AN/A

Current Analyst Ratings Breakdown

Latest GLMD Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/17/2026
Galmed Pharmaceuticals Ltd. stock logo
GLMD
Galmed Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
(Data available from 8/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Galmed Pharmaceuticals Ltd. stock logo
GLMD
Galmed Pharmaceuticals
N/AN/AN/AN/A$2.88 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Galmed Pharmaceuticals Ltd. stock logo
GLMD
Galmed Pharmaceuticals
-$10.31M-$0.91N/AN/AN/AN/A-35.32%-30.94%8/6/2026 (Estimated)

Latest GLMD Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2026N/A
Galmed Pharmaceuticals Ltd. stock logo
GLMD
Galmed Pharmaceuticals
-$0.39N/AN/AN/AN/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Galmed Pharmaceuticals Ltd. stock logo
GLMD
Galmed Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Galmed Pharmaceuticals Ltd. stock logo
GLMD
Galmed Pharmaceuticals
N/A
7.71
7.71

Institutional Ownership

CompanyInstitutional Ownership
Galmed Pharmaceuticals Ltd. stock logo
GLMD
Galmed Pharmaceuticals
76.14%

Insider Ownership

CompanyInsider Ownership
Galmed Pharmaceuticals Ltd. stock logo
GLMD
Galmed Pharmaceuticals
19.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
Galmed Pharmaceuticals Ltd. stock logo
GLMD
Galmed Pharmaceuticals
206.60 million5.29 millionNot Optionable

Recent News About These Companies

Galmed Pharmaceuticals (NASDAQ:GLMD) Stock Passes Below 200 Day Moving Average - Here's Why
August 4 at 3:41 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30940163
Galmed Pharmaceuticals Develops Oral Film Version of Parkinson's Treatment
July 30, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/galmed-pharmaceuticals-develops-oral-film-124246416.html
Galmed Pharmaceuticals Drops Yissum License to Sharpen Focus on Colospan and Aramchol
July 29, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/galmed-pharmaceuticals-drops-yissum-license-to-sharpen-focus-on-colospan-and-aramchol?utm_source=marketbeat.com&utm_medium=referral
Galmed Announces Breakthrough Development of Dispersible Film Delivery (ODF), Brain Penetrating formulation of its SCD1 inhibitor Aramchol for Parkinson's Disease, Targeting $6 ...
July 28, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/galmed-announces-breakthrough-development-dispersible-110000638.html
Galmed Announces Breakthrough Development of Dispersible Film Delivery (ODF), Brain Penetrating formulation of its SCD1 inhibitor Aramchol for Parkinson's Disease, Targeting $6 Billion Market
July 28, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/galmed-announces-breakthrough-development-of-dispersible-film-delivery-odf-brain-penetrating-formulation-of-its-scd1-inhibitor-aramchol-for-parkinsons-disease-targeting-6-billion-market-302836361.html
Galmed Announces the Breakthrough Development of Novel LNP Cardiac Targeted Formulation of its SCD1 inhibitor, Aramchol
July 16, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/galmed-announces-the-breakthrough-development-of-novel-lnp-cardiac-targeted-formulation-of-its-scd1-inhibitor-aramchol-302827443.html
Galmed and Tissue Dynamics Reveal New Metabolic Target for Cardiac Fibrosis With Aramchol Combo
June 24, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/GLMD/pressreleases/2280210/galmed-and-tissue-dynamics-reveal-new-metabolic-target-for-cardiac-fibrosis-with-aramchol-combo/
Galmed Pharmaceuticals Ltd. Announces Restructured Acquisition Terms for Colospan Ltd., Prioritizing CG-100 European Commercialization and Shareholder Value Protection and ...
June 22, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/galmed-pharmaceuticals-ltd-announces-restructured-110000398.html
Galmed Pharmaceuticals Ltd. Announces Restructured Acquisition Terms for Colospan Ltd.
June 22, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/galmed-pharmaceuticals-ltd-announces-restructured-acquisition-terms-for-colospan-ltd-prioritizing-cg-100-european-commercialization-and-shareholder-value-protection-and-consummation-of-acquisition-302806225.html
Galmed Pharmaceuticals Ltd. Ordinary Shares (GLMD)
June 10, 2026  |  nasdaq.comhttps://www.nasdaq.com/market-activity/stocks/glmd/advanced-charting
Galmed Pharmaceuticals Ltd.: Galmed Pharmaceuticals to Acquire Colospan to Create a GI-Focused Platform Targeting a $6 Billion Market
June 8, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-06/68709245-galmed-pharmaceuticals-ltd-galmed-pharmaceuticals-to-acquire-colospan-to-create-a-gi-focused-platform-targeting-a-dollar-6-billion-market-008.htm
Galmed Pharmaceuticals to Acquire Colospan to Create a GI-Focused Platform Targeting a $6 Billion Market
June 8, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/galmed-pharmaceuticals-to-acquire-colospan-to-create-a-gi-focused-platform-targeting-a-6-billion-market-302793948.html
Tissue Dynamics and Galmed Unveil Unknown Metabolic Pathway for Cardiac Fibrosis and Heart Failure which Supports the Development of Aramchol for Cardiac Fibrosis
June 2, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/tissue-dynamics-and-galmed-unveil-unknown-metabolic-pathway-for-cardiac-fibrosis-and-heart-failure-which-supports-the-development-of-aramchol-for-cardiac-fibrosis-302788311.html
Galmed Announces Results from First-in-Man Pharmacokinetics Study of Oral Formulation of Aramchol Meglumine (AM); 400mg AM Increases Bioavailability by ~500% in Comparison to Aramchol Free Acid (AA) 300mg
May 14, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/galmed-announces-results-from-first-in-man-pharmacokinetics-study-of-oral-formulation-of-aramchol-meglumine-am-400mg-am-increases-bioavailability-by-500-in-comparison-to-aramchol-free-acid-aa-300mg-302772195.html
Tissue Dynamics and Galmed Pharmaceuticals to Develop Human-Centered Chronic Cardiac Fibrosis Platform to Advance Aramchol-Based Therapeutics
May 6, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/tissue-dynamics-and-galmed-pharmaceuticals-to-develop-human-centered-chronic-cardiac-fibrosis-platform-to-advance-aramchol-based-therapeutics-302763979.html
Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Short Interest Update
April 25, 2026  |  defenseworld.netD
Galmed Announces a Collaboration Agreement with Tel Aviv University to Evaluate its SCD1 inhibitor, Aramchol, as a Targeted Therapy for Metastatic Brain Cancers
April 14, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/galmed-announces-a-collaboration-agreement-with-tel-aviv-university-to-evaluate-its-scd1-inhibitor-aramchol-as-a-targeted-therapy-for-metastatic-brain-cancers-302741560.html
GLMD stock shot up 85% pre-market after rising 27% in 5 days – what’s the latest on its Parkinson’s disease therapy?
April 9, 2026  |  msn.comhttps://www.msn.com/en-us/health/other/glmd-stock-shot-up-85-pre-market-after-rising-27-in-5-days-what-s-the-latest-on-its-parkinson-s-disease-therapy/ar-AA20vbs0
Galmed Stock Soars On Brain-Penetrating Aramchol Formulation
April 9, 2026  |  benzinga.comhttps://www.benzinga.com/trading-ideas/movers/26/04/51733792/galmed-stock-soars-on-brain-penetrating-aramchol-formulation
Galmed Announces the Breakthrough Development of a Brain Penetrating New Formulation of its SCD1 inhibitor, Aramchol
April 9, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/galmed-announces-the-breakthrough-development-of-a-brain-penetrating-new-formulation-of-its-scd1-inhibitor-aramchol-302738096.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Galmed Pharmaceuticals stock logo

Galmed Pharmaceuticals NASDAQ:GLMD

$0.60 +0.02 (+3.28%)
Closing price 08/6/2026 04:00 PM Eastern
Extended Trading
$0.60 +0.01 (+1.00%)
As of 08/6/2026 05:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas